Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
暂无分享,去创建一个
R. Figlin | R. Motzer | M. Michaelson | B. Redman | G. Wilding | B. Rini | M. Ginsberg | C. Baum | G. Hudes | D. George | C. Theuer | Samuel E DePrimo | Daniel J George | George Wilding | Robert A Figlin | Brian I Rini | Charles P Theuer | Bruce G Redman | Jim Z. Li | Robert J Motzer | Michelle S Ginsberg | Carlo L Bello | Charles M Baum | M Dror Michaelson | Sindy T Kim | Gary R Hudes | Jim Z Li | S. Deprimo | C. Bello | Sindy T. Kim
[1] Gareth Griffiths,et al. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. , 1999, Lancet.
[2] J. Rossi,et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Ravaud,et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .
[4] M. Heinrich,et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] Gerald McMahon,et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. , 2003, Cancer research.
[6] D. Hicklin,et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. , 2004, Molecular cancer research : MCR.
[7] A. Luttun,et al. VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis , 2003, Cell and Tissue Research.
[8] Randy Allred,et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.
[9] R. Motzer. Renal cell carcinoma: a priority malignancy for development and study of novel therapies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Kibel,et al. Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.
[11] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[12] William Kim,et al. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. , 2003, Current opinion in genetics & development.
[13] N. Pryer,et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. , 2003, Molecular cancer therapeutics.
[14] D. Hicklin,et al. Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies , 2004, Cancer Research.
[15] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[16] R. Motzer,et al. Systemic therapy for renal cell carcinoma. , 2000, The Journal of urology.
[17] R. Motzer,et al. Renal-cell carcinoma. , 1996, The New England journal of medicine.
[18] M. Heinrich,et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.
[19] T. Shuin,et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters , 2002, Genes, chromosomes & cancer.
[20] G. Semenza. Angiogenesis in ischemic and neoplastic disorders. , 2003, Annual review of medicine.
[21] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[22] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[23] R. Fisher,et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Ellis. Antiangiogenic therapy at a crossroads: clinical trial results and future directions. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Hanahan,et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.
[26] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[27] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[28] M. Ratain,et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[30] W. Kaelin,et al. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. , 2003, The New England journal of medicine.
[31] J. Herman,et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[32] D. Cella,et al. Fatigue in cancer patients compared with fatigue in the general United States population , 2002, Cancer.
[33] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[34] W. Kaelin. The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer , 2004, Clinical Cancer Research.
[35] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[37] Jeffrey A. Johnson,et al. Comparison of the EQ-5D and SF-12 in an adult US sample , 1998, Quality of Life Research.
[38] L. Schwartz,et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[40] Tamas Beothe,et al. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. , 2003, Cancer research.